Geneva, Switzerland and Boston, MA – April 1, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced that Company Management will be participating in three upcoming investor conferences.
- The H.C. Wainwright Global Life Sciences Conference taking place in London, April 7-9, 2019. ObsEva will present on Monday, April 8, 2019, at 3:30 p.m. Greenwich Mean Time (GMT).
- The Needham Healthcare Conference taking place in New York April 9-10, 2019. ObsEva will present on Wednesday, April 10 at 12:50 p.m. Eastern Time (ET).
- The Kempen Life Sciences Conference taking place in Amsterdam, April 16–17, 2019.
The H.C Wainwright Global Life Sciences and Needham Healthcare Conference presentations will be webcast, and available in the “Investors” section of ObsEva’s website www.ObsEva.com.
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.
For further information, please contact:
Media Contact Switzerland and Europe:
+41 22 308 6220 Office
+41 79 476 26 87 Mobile
Media Contact U.S.:
+1 212 223 4017 Office
+1 646 537 5649 Mobile
CEO Office Contact:
+41 22 552 1550
Senior Director, Investor Relations
+1 857 972 9347 Office
+1 781 366 5726 Mobile